NCT06844565Completed
Role of IL 12 and IL 23 as Potential Biomarkers in Diagnosis of Early Crohn's Disease
Source: ClinicalTrials.gov · Last updated 25 Feb 2025
Brief summary (registry, in English)
This study aims to evaluate the role of Interleukin (IL)-12 and IL-23 as potential biomarkers in the diagnosis of early Crohn's disease.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 110 (actual)
- First submitted
- 19 Feb 2025
- Start date
- 1 Jan 2021
- Primary completion date
- 31 Dec 2023
- Lead sponsor
- Tanta University
- Diseases
- Crohn's disease
- NCT number
- NCT06844565
What you commit to
- Study type: Observational
- Participants enrolled: 110
- From 1 Jan 2021 to the primary completion date, 31 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Immunosuppressive therapy or biologic agents at the time of study.
- Previous abdominal surgeries.
Other illness
- History of other significant gastrointestinal diseases (e.g., colon cancer, ischemic bowel disease).
Other
- Patients with no pathological samples through colonoscopy.
Who the study is looking for
- Age from 18 to 65 years.
- Both sexes.
- Patients who are suspected of having Crohn's disease clinically and by colonoscopy (like ulcers, fistulas, or skip lesions).
- Non-specific ileitis by histopathology.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tanta university Coordinator of this site? Confirm its status | Tanta | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.